Pre-hospital antithrombotic drug use status of died COVID-19 patients

Abstract

Objectives: In this study, we determine the prehospital antithrombotic drug use rates of patients in Covid-19 mortality to reveal the differences between patients using antithrombotic drugs and those who did not to show whether antithrombotic drugs impact the duration of stay in intensive care. Methods: This retrospective study was conducted with 291 patients admitted to the xxx University Training and Research Hospital emergency department between March 13 and December 1, 2020. Patients whose PCR test was positive and who died in our hospital were included in the study. Results: The median number of days in the intensive care unit of patients using acetylsalicylic acid (7; 3-11) was longer than patients who were not using acetylsalicylic acid (5; 1-10) (p=0.041). Also, the median days in the intensive care unit of patients who were not using any antithrombotic drug (5; 1-10) was shorter than patients who were using an antithrombotic drug (7;3-11) (p=0.032). There was no difference in patients using or not using other antithrombotic drugs (p=0.640) or acetylsalicylic acid and other antithrombotic drugs (p=0.979). Conclusion: This study shows that the prehospital use of aspirin has a positive effect on survival as it prolongs the length of stay in the intensive care unit. Since it is known that one of the most important causes of death in Covid-19 is hypercoagulopathy and considering the irreversible antiplatelet activity of aspirin and since this activity lasts for up to 10 days, the result seems reasonable.

Keywords

• Covid-19
• acetylsalicylic acid
• prehospital
• antithrombotic

References

1. Rico-Mesa JS, Rosas D, Ahmadian-Tehrani A, White A, Anderson AS, Chilton R. The tole of anticoagulation in COVID-19-induced hypercoagulability. Curr Cardiol Rep 2020; 22: 53.
2. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 1421-4.
3. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-7.
4. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46: 1089–98.
5. de Stoppelaar SF, van ’t Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost 2014; 112: 666–77.
6. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e24S-e43S.
7. Bikdeli B, Madhavan MV, Gupta A, et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020; 120: 1004–24.
8. Mycroft-West C, Su D, Elli S, et al. The 2019 coronavirus (SARS-cov-2) surface protein (spike) s1 receptor binding domain undergoes conformational change upon heparin binding. BioRxiv 2020: 2020.2002.2029.971093

9. Boyle AJ, Di Gangi S, Hamid UI, et al. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care Lond Engl 2015; 19: 109.
10. Wang L, Li H, Gu X, Wang Z, Liu S, Chen L. Effect of antiplatelet therapy on acute respiratory distress syndrome and mortality in critically ill patients: a meta-analysis. PloS One 2016; 11: e0154754.
11. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–94.
12. COVID-19 Rehberi. 2020. Available from: https://covid19bilgi.saglik.gov.tr/depo/rehberler /COVID-19_Rehberi.pdf
13. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094–9.
14. Gupta N, Zhao Y-Y, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res 2019; 181: 77–83.
15. Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost JTH 2020; 18: 1517–9.
16. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 20209; 383: 120–8.
17. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135: 2033–40.
18. Jin J-M, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 2020; 8: 152.
19. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol 2019; 56: 308–21.
20. Hewagama A, Patel D, Yarlagadda S, Strickland FM, Richardson BC. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun 2009; 10: 509–16.
21. W-j G, Liang W-h, Zhao Y, et al. Comorbidity and its impact on 1,590 patients with COVID-19 in China: a Nationwide analysis. medRxiv. 2020.
22. Mutlu H, Sert ET, Kokulu K, Saritas A. Anxiety level in pre-hospital emergency medical services personnel during coronavirus disease-2019 pandemic. Eurasian J Emerg Med 2021; 20:43-48.
23. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis off Publ Infect Dis Soc Am 2000; 31: 578–85.
24. Quiros-Roldan E, Biasiotto G, Zanella I. Letter to the Editor on ‘Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev'. Cytokine Growth Factor Rev 2020; 54: 1–2.
25. Sousa GJB, Garces TS, Cestari VRF, Florêncio RS, Moreira TMM, Pereira MLD. Mortality and survival of COVID-19. Epidemiol Infect 2020; 148: e123.
26. Chow JH, Khanna AK, Kethireddy S, et al. Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19. Anesth Analg 2020: 1-41.
27. Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine 2020; 24: 100434.